テルビナフィン
テルビナフィンは、経口および外用製剤として利用可能な合成**アリルアミン系抗真菌薬**です。 **主な臨床的特徴:** * **主な用途:** 犬や猫の皮膚糸状菌感染症(小胞子菌、白癬菌など)に非常に有効です。また、特に鳥類における全身性真菌感染症(アスペルギルス症など)の治療にも使用されます。 * **良好な相互作用プロファイル:** アゾール系抗真菌薬(ケトコナゾール、イトラコナゾールなど)とは異なり、テルビナフィンの主な作用機序はシトクロムP-450酵素系に依存しないため、薬物相互作用が著しく少なく、哺乳類のテストステロンやコルチゾール合成を抑制しません。 * **薬理学的特徴:** テルビナフィンは高い脂溶性と**親ケラチン性**を持っています。皮膚、皮脂、毛包に広く分布し、治療中止後も数週間にわたってこれらの組織で治療濃度を維持します(これによりパルス療法が可能になります)。 * **忍容性:** 獣医療において一般的に非常に忍容性が高く、最もよく報告される副作用は軽度の胃腸障害(嘔吐)です。
作用機序: Terbinafine exerts its antifungal activity by interfering with fungal sterol biosynthesis at an early stage. * It selectively and reversibly inhibits the fungal enzyme **squalene monooxygenase** (also known as squalene 2,3-epoxidase). * This blockade prevents the conversion of squalene to lanosterol → leading to a profound deficiency of **ergosterol** (a critical component of the fungal cell membrane). * Simultaneously, the inhibition causes an intracellular **accumulation of squalene**, which is directly toxic to the fungal cell, leading to rapid cell death. This dual mechanism makes terbinafine primarily **fungicidal** against dermatophytes, though it may only be **fungistatic** against certain yeasts like *Candida spp.*
動物種別の用量
- Dermatophytic infections (Pulse therapy) · 20 mg/kg · PO · q24h · 7 days on, then 21 days off · Maintained terbinafine concentrations in hair above therapeutic levels. Higher doses (40 mg/kg) or continuous administration caused emesis and elevated hepatic enzymes.
- Dermatophytic infections · 10-20 mg/kg · PO · q24h · Appears to be better tolerated than either ketoconazole or itraconazole.
- Dermatophytic infections (when other drugs are not tolerated) · 25 mg/kg · PO · q24h
- Dermatophyte (M. canis) mycetomas · 26-31 mg/kg · PO · q24h · 12-14 weeks · Achieved clinical and mycological cure in a case report of two cats.
- Cryptococcal infections (azole-resistant) · 10 mg/kg · PO · q24h · Life-long · Can rectify clinical signs, though cats with CNS cryptococcus usually require treatment for life.
- Antifungal (Systemic/Dermatophytosis) · 20-40 mg/kg · PO · q24h · Not specified
- Localized Malassezia infections · Apply a thin layer · topical · Not specified · Not specified · Use 1% cream.
- Avian mycotic infections (Aspergillus) · 10-15 mg/kg · PO · q12-24h · Appears to be well tolerated by a number of avian species.
- Avian mycotic infections (Aspergillus) · 1 mg/mL aqueous solution · Nebulization · Not specified
投与経路
禁忌
- Known hypersensitivity to terbinafine
- Active or chronic liver disease
- Significantly impaired renal function
- Perforated eardrum (for ear gel administration)
- Generalized demodicosis (topical or systemic use)
- Pregnant animals
- Breeding animals
有害事象
- Vomiting
- Inappetence
- Diarrhea
- Lethargy (reported in cats)
- Hepatotoxicity / Liver failure (very rare, reported in humans)
- Neutropenia (very rare, reported in humans)
- Serious skin reactions like Toxic Epidermal Necrolysis or Stevens-Johnson syndrome (very rare, reported in humans)
- Diarrhoea
- Increased liver enzymes
- Pruritus (cats)
- Topical irritation (due to alcohol content in topical solutions)
- Transient deafness or impaired hearing (in elderly dogs after administration of ear gel)
薬物相互作用
- Cyclosporine · Terbinafine may increase the elimination and decrease the efficacy of cyclosporine.
- Rifampin · May increase terbinafine clearance, potentially requiring higher terbinafine doses. · moderate
- Beta-blockers · Terbinafine shares the CYP2D6 metabolic pathway and could theoretically alter the metabolism of beta-blockers.
- MAO Inhibitors (e.g., amitraz, selegiline) · Terbinafine shares the CYP2D6 metabolic pathway and could theoretically alter the metabolism of MAOIs.
- SSRIs (e.g., fluoxetine) · Terbinafine shares the CYP2D6 metabolic pathway and could theoretically alter the metabolism of SSRIs.
- Tricyclic Antidepressants · Terbinafine shares the CYP2D6 metabolic pathway and could theoretically alter the metabolism of TCAs.
- Cimetidine · May decrease the clearance of terbinafine, potentially increasing plasma concentrations (Clinical Pearl) · moderate
モニタリング
- Clinical efficacy (resolution of fungal lesions)
- Baseline liver enzymes prior to therapy
- Periodic liver enzyme monitoring as needed, especially during long-term treatment
- CBC (baseline and periodic)
- Liver function tests (ALT, AST, Bilirubin)
- Renal function tests
- Clinical response (skin scrapings, fungal cultures)
過量投与
There is limited information regarding acute toxicity in veterinary species. In humans, acute ingestions of up to 5 grams have been reported without serious adverse effects. Treatment of massive overdose should be supportive and symptomatic.
VetSheet の薬剤リファレンスは、獣医療従事者向けの臨床意思決定支援を目的としており、専門的判断やメーカーの最新添付文書に代わるものではありません。